| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcba9844714c559175a2242c7a306692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7c109e96ea002b896c90befc5cf334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26e5a9def44a2e824163e6d49c26d3b0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2015-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8cafdb4c218abec7d2af8215a9ea3f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db3fc38c3e1c7a1fd2ac60bde59119c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c1e28b7df096c0853ddd739a4a6edfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_989fa2343bdc8b85b50d0a73a3efeb42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1269009a8a418f5b1b5c500659a02dba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3b7cbee286670f874e1aba82cd3d84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5e432e24425467a3d811bdec1359095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56f5a5d5d0ca30a4cef6ae6763ed30a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a081068dc17c6126273baa05ee76fd4 |
| publicationDate |
2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3105350-A2 |
| titleOfInvention |
Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure |
| abstract |
The invention relates to biomarkers for individual risk assessment of the development of post-infarction heart failure, the method of determining the markers in samples of biological material collected from a patient. Further, the invention relates to a use of the biomarkers in the diagnosis (expression level of the gene) that correlate with the developing post-infarction heart failure, and enable prevention of heart disease based on a genetic marker and a method for predicting the risk of developing a heart failure for post-infarction patients. Also a method for optimizing the treatment of cardiac patients with the use of the means of the invention is disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102020205364-B4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102020205364-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021219604-A1 |
| priorityDate |
2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |